Europe Allows Derogation of Atypical Actives from ICH Q7
This article was originally published in The Gold Sheet
Executive Summary
The European Medicines Agency tackled the issue of atypical actives in 2008, David Cockburn, head of manufacturing quality compliance at EMA, told a recent PDA workshop in Bethesda, Md.
You may also be interested in...
Threat of Sanctions, Shortages, Spurs Talk of Standards for Atypical Actives
As the pharmaceutical supply chain comes under increased regulatory scrutiny, FDA inspectors are finding manufacturers using excipients as active ingredients, even though they don’t meet active ingredient standards, and the industry is talking about establishing a new set of standards for these so-called atypical actives, and perhaps coaxing FDA into ratifying them via guidance.
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.